New nasal spray aims to zap migraine pain in 2 hours
NCT ID NCT06103734
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a nasal spray called zavegepant could relieve migraine pain within 2 hours. Adults with migraines for at least a year were to use the spray at home for up to 4 attacks. The study was withdrawn before enrolling participants, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Expected to start
-
Sep 2025
An estimate. Start dates often move.
- Expected to finish
-
Aug 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Participants aged 18 years or older. 2. Participants with minimum 1 year history of migraine with age onset before 50 years of age. Exclusion Criteria: 1. History of retinal migraine, basilar migraine or hemiplegic migraine. 2. History or current evidence of uncontrolled, unstable or recently diagnosed cardiovascular or cardiometabolic disease. 3. Major depressive disorder or anxiety disorder. 4. Acute or chronic pain syndromes. 5. Conditions that may affect the administration or absorption of the nasal product. 6. History of alcohol abuse and/or illicit drug. 7. Other social, medical, or psychiatric condition that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. 8. Current use of any prohibited concomitant medication(s) or participants unwilling/unable to use a permitted concomitant medication(s) 9. History of use of ergotamine medications or triptans on greater than/equal to 10 days per month on a regular basis for greater than/equal to 3 months. Or history of non-narcotic analgesic intake on greater than/equal to 15 days per month for greater than/equal to 3 months for other pain indications. 10. Participation in clinical trial with non-biological investigational agents or interventional treatments (last study visit occurring) within the 30 days prior to Baseline Visit. Participation in clinical trial with biological investigational agents (last study visit occurring) within 90 days prior to Baseline Visit. Participation in any other investigational clinical trial while participating in this clinical trial. 11. Previous participation in any zavegepant study within the last 2 years. 12. ANY of the following findings at the Screening Visit and laboratory tests as assessed by the study-specific laboratory: 1. Class 2 or Class 3 obesity, defined as body mass index \>35 kg/m2. 2. Estimated Globular Filtration Rate \<30 mL/min/1.73 m2. 3. Total bilirubin ≥1.5 × upper limit of normal. 4. Liver transaminases ≥2.0 × upper limit of normal . 5. Neutrophil count ≤1000/μL (or equivalent).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Migraine are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to dozens of diseases
- Blood, tears and saliva: the hunt for Migraine's hidden signature
- Could your toothpaste be triggering migraines? trial puts it to the test
- Can sleep, neck pain, and fatigue explain Migraine's daily toll?
- Do Gender-Affirming hormones trigger headaches? thai survey probes the question
- Can a pill stop a migraine in two hours?